In March 2021, pembrolizumab plus fluoropyrimidine- and platinum-based chemotherapy was authorized by the FDA for the first-line treatment of patients with ESCC and EAC with CPS ≥10 (category 1, requires combination with cisplatin) and CPS <10 (category 2B) (39). Here, CAD is linked to esophageal squamous cell carcinoma.